Answers are grounded in this paper and cite their sources.
This article outlines recent developments in non-allergist delivered penicillin allergy de-labelling (PADL), discusses remaining controversies and uncertainties and explores the future for non-allergist delivered PADL. Recent developments include national guidelines for non-allergist delivered PADL and validation of penicillin allergy risk assessment tools. Controversies remain on which penicillin allergy features are low risk of genuine allergy. In the future genetic or immunological tests may facilitate PADL.
No takes yet. Share an insight, caveat, or question.
Powell et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: